<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1033">
  <stage>Registered</stage>
  <submitdate>12/01/2006</submitdate>
  <approvaldate>12/01/2006</approvaldate>
  <nctid>NCT00277810</nctid>
  <trial_identification>
    <studytitle>Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease</studytitle>
    <scientifictitle>A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>3098B1-203, 3098B1-204</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - lecozotan SR (SRA-333)

Experimental: A - 

Experimental: B - 

Experimental: C - 


Treatment: drugs: lecozotan SR (SRA-333)
one of 3 doses of lecozotan sr dose for 6 months as an extesnion to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>All events and physical and neurological function and score change from baseline to 24 weeks in ratings for cognitive and global function scales</outcome>
      <timepoint>6 mo extension study: week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Score change from baseline to 24 weeks on functional and behavioral scales</outcome>
      <timepoint>week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of probable Alzheimer`s disease

          -  Current use of cholinesterase inhibitor

          -  Able to give signed and dated informed consent and lives with appropriate caregiver at
             home or in community dwelling with caregiver accompanying patient to all visits and
             visiting patient at least daily for duration of the study</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Significant neurological disease other than AD

          -  Diagnosis of major depression

          -  History of stroke or other heart disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>250</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - East Gosford</hospital>
    <hospital> - Hornsby</hospital>
    <hospital> - Randwick</hospital>
    <hospital> - Victoria</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>2250 - East Gosford</postcode>
    <postcode>2077 - Hornsby</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>3081 - Victoria</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Av. Belgrano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Calle Adolfo Alsina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cervino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Galvan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Gascon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Larrea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Nueva York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Pilar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Joensuu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk - Wrzeszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Sopot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Szczecin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Somerset West</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Belfast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Swindon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Wyeth is now a wholly owned subsidiary of Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of
      lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate
      Alzheimer's disease (AD).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00277810</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor</name>
      <address>Wyeth is now a wholly owned subsidiary of Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>